{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:06:39Z","timestamp":1776276399362,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virol.2026.110879","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:59:58Z","timestamp":1773421198000},"page":"110879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hepatitis D Infection: a puzzle still unsolved?"],"prefix":"10.1016","volume":"619","author":[{"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"Boccellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Polito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-2171","authenticated-orcid":false,"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2026.110879_bib1","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i6.107963","article-title":"Hope on the horizon: emerging therapies for hepatitis D","volume":"17","author":"Abbas","year":"2025","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104995","article-title":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis","volume":"185","author":"Abdrakhman","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2026.110879_bib3","first-page":"1520","article-title":"Chronic hepatitis D infection and carcinogenesis","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2026.110879_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of rep 2139 and pegylated interferon alfa- 2a for treatment- naive patients with chronic hepatitis B virus and hepatitis D virus co- infection (Rep 301 and Rep 301- LTF): a non- randomised, open- label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib6","first-page":"1427","article-title":"First-in-human application of bulevirtide in HDV infection","volume":"16","author":"Blank","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2026.110879_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.virol.2026.110879_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib11","article-title":"Tobevibart (VIR-3434), an anti-HBsAg monoclonal antibody in chronic hepatitis B: early phase results","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib12","first-page":"1370","article-title":"Hepatitis delta virus persistence and innate immune activation","volume":"67","author":"Giersch","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11901-024-00643-w","article-title":"Advances and challenges in managing hepatitis D virus: evolving strategies","volume":"23","author":"Gopalakrishna","year":"2024","journal-title":"Curr. Hepat. Rep."},{"issue":"1","key":"10.1016\/j.virol.2026.110879_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2026.110879_bib15","first-page":"1197","article-title":"Liver-resident CD8+ T cells contribute to liver disease pathogenesis in chronic hepatitis D","volume":"10","author":"Kefalakes","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2026.110879_bib16","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis \u2013 end of study results from the LOWR HDV-3 study","volume":"66","author":"Koh","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib17","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA \u2014 the holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.virol.2026.110879_bib18","article-title":"Epatocarcinoma da HDV: un vero rompicapo patogenetico","author":"Pollicino","year":"2025","journal-title":"READfiles"},{"key":"10.1016\/j.virol.2026.110879_bib19","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"28-Year study of the course of hepatitis \u0394 infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"36","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virol.2026.110879_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S379964","article-title":"Bulevirtide in the treatment of hepatitis Delta: drug discovery, clinical development and place in therapy","volume":"17","author":"Soriano","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.virol.2026.110879_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2026.110879_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/liv.15387","article-title":"Future anti-HDV treatment strategies, including those aimed at HBV functional cure","volume":"43","author":"Tan","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.virol.2026.110879_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in HBV\/HDV coinfection","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2026.110879_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2026.110879_bib25","series-title":"Global Hepatitis Report","year":"2017"},{"key":"10.1016\/j.virol.2026.110879_bib28","first-page":"1177","article-title":"Long-term outcomes and relapse patterns in chronic hepatitis D","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2026.110879_bib29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose-optimization study of lonafarnib with ritonavir for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.virol.2026.110879_bib26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.virol.2026.110879_bib27","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226000942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:19:26Z","timestamp":1776273566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S0042682226000942"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.110879","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis D Infection: a puzzle still unsolved?","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.110879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110879"}}